An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape.

ABSTRACT:

Background

Immunotherapy has demonstrated limited activity in prostate cancer to date. This likely reflects an immune suppressive tumor microenvironment (TME), with previous studies suggesting low PD-L1 expression and a sparse immune cell infiltrate. We aimed to further characterise the immune TME in primary prostate cancer and correlate immune subset densities with clinical outcomes.

Methods

Two distinct cohorts of patients treated with radical prostatectomy were identified, based on the development of biochemical recurrence (BCR), one subgroup with high International Society of Urological Pathologists (ISUP) grade group, recurrent disease and a second with low grade, non-recurrent disease. A prostate immunohistochemical (IHC) antibody cocktail was used to differentiate tum

SUBMITTER: Anton A 

PROVIDER: S-EPMC11602054 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature